Results 121 to 130 of about 4,064 (194)

Evaluation of QIAreach QuantiFERON-TB lateral-flow nanoparticle fluorescence assay for TB infection diagnosis among TB household contacts in three high-burden settings.

open access: yesPLoS ONE
BackgroundTuberculosis infection (TBI) testing, and treatment are fundamental to achieve TB elimination. TBI testing among close or household contacts (HHCs) has been limited, in part due to perceived complexity and high operational cost.
Thobani Ntshiqa   +22 more
doaj   +1 more source

Evaluation of three novel antigens and costimulatory agents for improvement of M. Tuberculosis specific interferon gamma release assays

open access: yesBMC Infectious Diseases
Background Mycobacterium tuberculosis (MT) infections represent a global health problem and latent tuberculosis infection (LTBI) affects an estimated 25% of the world population. 10.6 million people fell ill with tuberculosis (TB) worldwide in 2021 and a
Sandra Schwarzlose-Schwarck   +9 more
doaj   +1 more source

Reversions of QuantiFERON-TB Gold Plus in tuberculosis contact investigation

open access: yes
Interferon-y Release Assays (IGRA) reversions have been reported in different clinical scenarios for the diagnosis of tuberculosis (TB) infection. This study aimed to determine the rate of QuantiFERON-TB Gold Plus (QFT-Plus) reversions during contact investigation as a potential strategy to reduce the number of preventive treatments.
Pérez-Recio, Sandra   +19 more
openaire   +1 more source

Project #28: DOES ANYONE REALLY KNOW WHAT TIME IT IS? [PDF]

open access: yes
Problem Statement: Due to the increased amount of QuantiFERON®-TB Gold Plus testing, the number of timers alarming in the lab is disruptive to accessioning and leaves room for errors. Specimens are being pulled too early or left in the incubator for too
Burke, Jessica A   +5 more
core   +1 more source

High prevalence of latent tuberculosis using the QuantiFERON-TB Gold Plus test in Takayasu arteritis. [PDF]

open access: yesArch Rheumatol, 2022
Souza Pedreira AL   +3 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy